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Abstract
Background: The pathogenesis of severe dengue has not been fully elucidated. The inflammatory response plays a
critical role in the outcome of dengue disease.
Methods: In this study, we investigated the levels of 17 important inflammation mediators in plasma collected
from mild or severe adult dengue patients at different time points to understand the contribution of inflammation
to disease severity and to seek experimental evidence to optimize the existing clinical treatment strategies. Patients
were simply classified as mild and severe dengue according to the 2009 WHO classification. Plasma was collected
on day 3-5, 6-7, 8-10 and 14-17 of illness. Levels of 17 inflammation mediators including TNF-α, IL-1α, IFN-γ, IL-6,
IFN-α, MIF, IL-10, IL-1RA, IL-8, IP-10, MCP-1, RANTES, GRO, eotaxin-1, sICAM-1 and sVCAM-1 were determined by a
multiplex Luminex® system. Different trends of inflammation mediators throughout the disease were compared
between mild and severe patients.
Results: Inflammation mediators including IL-1α, IFN-γ, IL-10, IL-8, IP-10, MCP-1 and sVCAM-1 displayed significant
differences on day 8-10 of illness between mild and severe dengue patients. Their concentrations were higher in
severe patients than mild ones at the same time points. Moreover, those cytokines decreased gradually in mild
patients but not in severe patients.
Conclusion: Our results revealed the coexistence of excessive inflammatory response and slow resolution of
inflammation in severe adult dengue patients. Hence suppression and/or pro-resolution of inflammation could be a
potential therapeutic approach for treatment of severe dengue.
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Background
Dengue, caused by dengue virus (DENV) infection, is
considered as the most prevalent mosquito-borne viral
disease in humans. An estimated 390 million individuals
are infected annually by DENV in tropical and subtrop-
ical regions [1]. All four serotypes of DENV (DENV-1 to
DENV-4) can cause a spectrum of illness ranging from
asymptomatic to life-threatening dengue shock syn-
drome [2]. Symptomatic disease includes two entities:
mild and severe dengue according to the 2009 World
Health Organization (WHO) classification [3]. Mild den-
gue is a self-limited illness lasting about 7 days. How-
ever, severe dengue, characterized by plasma leakage,
may be fatal. Although many efforts have been made to
elucidate the underlying mechanisms of severe disease, it
still remains unclear [4, 5].
The inflammatory response against DENV is believed
to play an important role in its pathogenesis [6]. The dif-
ferent manifestations between mild and severe dengue
patients indicate that inflammatory response may differ
substantially. Many studies have demonstrated that
levels of inflammation mediators such as TNF-α, IFN-γ,
IP-10, IL-8 are elevated in dengue patients and higher
levels in severe cases [7–9]. It has been suggested that
inflammation plays a critical role in the outcome of
DENV infection. The inflammation is beneficial in
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providing protection against infection and normally ter-
minated once the infection is cleared, while it is detri-
mental when dysregulated [10, 11]. Similar to the
initiation of inflammation, the resolution of inflamma-
tion would be crucial for a successful outcome [12].
Dengue is an expanding public threat to people in
South China, where the patients exhibit different symp-
toms comparative to Southeast Asia. In Southeast Asia,
children have greater risk of severe disease while adults
show a mild disease. In 2013, China experienced a large
dengue outbreak after 1990s, which was especially preva-
lent in Xishuangbanna region in Yunnan province where
an autochthonous dengue outbreak has not been re-
corded in the last decade and Guangzhou city in Guang-
dong province where both incidence and case numbers
are the highest among Chinese cities [13]. A total of
4432 cases were reported and 86 were severe ones, with
an incidence rate of severe dengue of 1.9 % [14]. In this
study, we determined levels of 17 important inflamma-
tion mediators in plasma collected from mild or severe
adult dengue patients at different time points to under-
stand the contribution of inflammation to disease sever-
ity and to seek experimental evidence to optimize the
existing clinical treatment strategies.
Methods
Study subjects and samples
Fifty one dengue patients and 10 healthy volunteers
were included in this study from Guangzhou Eighth
People’s Hospital and Xishuangbanna Dai Autonomous
Prefecture People’s Hospital between August 20 and
November 15 in 2013. All patients were laboratory con-
firmed to have dengue by dengue virus specific anti-
body test and real-time PCR assay using serum samples
obtained during acute phase of infection. Patients were
classified as mild and severe dengue following the 2009
WHO dengue classification. With any of the following
conditions, cases were diagnosed as severe disease: (1)
plasma leakage leading to shock, respiratory distress, or
both; (2) severe bleeding; and (3) severe organ impair-
ment. Plasma of 51 patients was collected on day 3–5,
6–7, 8–10 and 14–17 of illness. Plasma was collected
from 10 age and gender matched healthy volunteers as
controls. All samples were stored at −80 °C. Data on
demographic characteristics, clinical features and rou-
tine laboratory test findings were also collected.
Diagnosis of primary or secondary infection
Dengue IgM and IgG capture ELISA kits (Panbio,
Brisbane, Queensland, Australia) were used to diag-
nose primary or secondary dengue infection according
to the manufacturer’s protocol using serum during
acute stage. Dengue-specific IgM positive only was in-
dicative of primary infection. Both IgM and IgG
positive or IgG positive only was diagnosed as sec-
ondary infection.
Serotype of DENV assay
Serotypes of DENV were determined by serotype spe-
cific fluorescent PCR diagnostic kits (DAAN Ltd,
Guangzhou, Guangdong, China) according to the man-
ufacturer’s protocol and performed on an ABI 7500
real-time PCR system (ABI, Foster city, CA).
Measurement of inflammation mediators
Inflammation mediators were measured using MILLI-
PLEX® MAP human cytokine/chemokine panel 1 kit and
human sepsis panel 1 kit (Merck Millipore, Germany)
according to the manufacturer’s instructions. Briefly, pa-
tients’ plasma was mixed with beads coated with capture
antibodies to various mediators. Then the mixtures were
incubated with biotinylated detection antibodies. Finally,
PE-conjugated streptavidin was added, and the fluores-
cent signals were detected using Luminex® 200™ System
(Life Technologies, Grand Island, NY). Raw data was ini-
tially measured as the relative fluorescence intensity and
then converted to concentration based on the standard
curves generated from the reference concentrations sup-
plied in the kits. 17 inflammation mediators were mea-
sured including tumor necrosis factor-α (TNF-α),
interleukin-1α (IL-1α), interferon-γ (IFN-γ), interleukin-6
(IL-6), interferon-α (IFN-α), macrophage migration inhibi-
tory factor (MIF), interleukin-10 (IL-10), interleuekin-1
receptor antagonists (IL-1RA), interleukin-8 (IL-8),
interferon-inducible protein-10 (IP-10), monocyte chemo-
tactic protein-1 (MCP-1), regulated upon activation nor-
mal T-cell expressed and secreted (RANTES), growth
related oncogene-α (GRO-α), eotaxin-1, soluble intercellu-
lar adhesion molecule-1 (sICAM-1) and soluble vascular
cell adhesion molecule-1 (sVCAM-1).
Statistical analysis
Data are reported as mean ± standard deviation (SD) for
clinical parameters. Statistical analysis was done using
GraphPad Prism 5.0 (GraphPad software, San Diego,
USA) by t tests or non-parametric tests. Differences of
P < 0.05 were considered statistically significant.
Results
Characteristics of dengue patients
Fifty one dengue patients were included in this study. 30
were diagnosed as mild dengue and 21 were severe ones.
Detailed demographic, epidemiologic and clinical fea-
tures of patients are summarized in Tables 1 and 2. All
patients were adults. Age was between 18 to 61 years
old. Laboratory tests on peripheral blood examination
were summarized in Table 2. Results showed that
leukopenia especially neutropenia and thrombocytopenia
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occurred in all patients but no increased hematocrit. Al-
bumin was decreased, while alanine aminotransferase
(ALT), aspartate aminotransferase (AST), creatine kinase
(CK), lactate dehydrogenase (LDH) increased in all pa-
tients. Platelet (PLT) was lower (P = 0.048) while AST
was higher (P = 0.021) in severe patients than mild ones.
Levels of inflammatory mediators and dynamic of
inflammation resolution at different time points in mild
and severe dengue patients
Levels of 17 inflammation mediators including 6 pro-
inflammatory cytokines, 2 anti-inflammatory cytokines,
7 chemokines and 2 adhesion molecules were deter-
mined in mild and severe dengue patients at four time
points, on day 3–5, 6–7, 8–10 and 14–17 of disease to
observe trends of the mediators over the course of dis-
ease. We chose to analyze levels of these mediators on
day 6–7 and 8–10 of illness in order to understand the
difference in inflammation resolution between mild and
severe dengue patients.
Pro-inflammatory cytokines
Six pro-inflammatory cytokines, including TNF-α, IL-1α,
IFN-γ, IL-6, IFN-α and MIF, were determined. As Fig. 1
shown, concentrations of TNF-α {P < 0.01 (Day 3-5), P <
0.01 (Day 6-7), P < 0.01 (Day 8-10), Fig. 1a}, IL-1α {P =
0.003 (Day 3–5), P < 0.01 (Day 6–7), P < 0.01 (Day 8–
10), Fig. 1b} and IFN-γ {P = 0.047 (Day 3–5), P = 0.074
(Day 6–7), P = 0.161(Day 8–10), Fig. 1c} were signifi-
cantly elevated in dengue patients compared to healthy
controls at early stage of illness. Then these cytokines
exhibited a decreasing trend as patients recovered {TNF-
α: P = 0.058 versus Controls (Day 14–17); IL-1α: P =
0.094 versus Controls (Day 14–17); IFN-γ: P = 0.919 ver-
sus Controls (Day 14–17)}. Moreover, higher level of
TNF-α (P =0.004) on day 6–7 and higher levels of IL-1α
(P = 0.012) and IFN-γ (P = 0.001) on day 8–10 of illness
were observed in severe dengue patients than mild
ones. However, IFN-α (P > 0.05, Fig. 1d), IL-6 (P > 0.05,
Fig. 1e) and MIF (P > 0.05, Fig. 1f ) did not display sig-
nificant abnormality at each time point. In addition, no
differences of IFN-α (P > 0.05, Fig. 1d), IL-6 (P > 0.05,
Fig. 1e) and MIF (P > 0.05, Fig. 1f ) were observed on
day 6–7 and on day 8–10 of illness between mild and
severe dengue patients.
Table 1 Demographic and epidemiologic features of mild and
severe dengue patients
Items Mild (n = 30) Severe (n = 21)
Age, median (range) 35 (18-59) 39(18-61)
Gender
Male, no. (%) 21 (70) 7 (33.3)
Female, no. (%) 9 (30) 14 (66.7)
Primary or secondary infection
Primary infection, no. (%) 21 (70) 11 (52.4)
Secondary infection, no. (%) 9 (30) 10 (47.6)
DENV serotype
DENV-1, no. (%) 22 (73.3) 10 (47.6)
DENV-3, no. (%) 8 (26.7) 11 (52.4)
Table 2 Clinical features and laboratory data from mild and
severe dengue patients




Myalgia or Arthralgia 63.3 52.4
Hypodynamia 50 100
Vomiting 16.7 28.6




Positive tourniquet test Not detected 94
Haemorrhagia 0 61.9
Plasma leakage 0 33.3
Hypotension 0 28.6
Laboratory data (Mean ± SD)
White Blood Cells count (×109/L) 3.7 ± 1.5 3.7 ± 2.1
Neutrophils count (×109/L) 1.9 ± 1.6 1.4 ± 0.8
Lymphocytes count (×109/L) 1.3 ± 0.7 1.8 ± 1.9
Monocytes count (×109/L) 0.4 ± 0.2 0.4 ± 0.2
CD3+T cells count (cells/μl) 1026 ± 552 957 ± 592
CD4+T cells count (cells/μl) 511 ± 280 493 ± 271
CD8+T cells count (cells/μl) 466 ± 322 442 ± 379
CD4/CD8 ratio 1.26 ± 0.80 1.37 ± 0.68
Hematocrit (HCT, %) 42 ± 9 39 ± 6
Platelet (×109/L) 75 ± 56 48 ± 33*
Total Billirubin (μmol/L) 12.19 ± 5.03 13.85 ± 7.90
Total Protein (g/L) 65 ± 6 62 ± 6
Albumin (g/L) 39 ± 4 36 ± 4
Alanine Transaminase (ALT, U/L) 60 ± 71 89 ± 60
Aspartate Transaminase (AST, U/L) 77 ± 65 126 ± 71*
Alkaline Phosphatase (ALP, U/L) 65 ± 23 96 ± 103
Creatine kinase (CK, U/L) 203 ± 140 231 ± 185
Lactate Dehydrogenase (LDH, U/L) 369 ± 165 490 ± 271
Creatinine (μmol/L) 79 ± 17 75 ± 43
*P < 0.05, severe patients vs mild patients
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Anti-inflammatory cytokines
IL-10, as one of the important anti-inflammatory cyto-
kines, was increased at early stage of illness in dengue
patients than healthy controls {P = 0.008 (Day 3–5), P =
0.001 (Day 6–7), P = 0.027 (Day 8–10), P = 0.098 (Day
14–17), Fig. 2a}. However, it showed different decreasing
patterns between mild and severe patients (Fig. 2a). Mild
dengue patients displayed decreased trends after day 6–
7 of illness (Fig. 2a). In contrast, increased trends were
observed in severe dengue patients (Fig. 2a). The con-
centration of IL-10 was significantly higher in severe
than mild patients on day 8–10 of illness (P = 0.003,
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Mild dengue (n = 30) 
3-5 d (n = 10)
6-7 d (n = 18)
8-10 d (n = 19 )
14-17d (n = 6)
Severe dengue (n = 21)
3-5 d (n = 3)
6-7 d (n = 9)
8-10 d (n = 11)
14-17d (n = 5)
Controls (n = 10)
Fig. 1 Dynamic changes of pro-inflammatory cytokines were compared in dengue patients. TNF-α (a), IL-1α (b) and IFN-γ (c) were significantly
elevated in dengue patients. Then they decreased as patients were recovery. Moreover, higher level of TNF-α on day 6-7 and higher levels of
IL-1α and IFN-γ on day 8-10 of illness were observed in severe dengue patients than mild ones. However, IFN-α (d), IL-6 (e) and MIF (f) did not
display significant abnormality at each time point. In addition, no differences of IFN-α, IL-6 and MIF were observed on day 6-7 and on day 8-
10 of illness between mild and severe dengue patients
a b
Mild dengue (n = 30) 
3-5 d (n = 10)
6-7 d (n = 18)
8-10 d (n = 19 )
14-17d (n = 6)
Severe dengue (n = 21)
3-5 d (n = 3)
6-7 d (n = 9)
8-10 d (n = 11)
14-17d (n = 5)
Controls (n = 10)
Fig. 2 Different trends of anti-inflammatory cytokines were observed between mild and severe dengue patients. IL-10 was increased at early
stage of illness in dengue patients. However, it showed different decreasing patterns between mild and severe patients (a). No abnormality was
observed with regard to IL-1RA at each time points between dengue patients and healthy controls (b)
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Fig. 2a). No significant difference was observed between
dengue patients and healthy controls with respect to
plasmatic IL-1RA concentration (P > 0.05, Fig. 2b).
Chemokines
Seven chemokines, including IL-8, IP-10, MCP-1,
RANTES, GRO-α, eotaxin-1 and MDC, were detected.
IL-8 was higher in severe patients than mild patients
and showed decreasing trends as patients recovered
{(P = 0.008 (Day 6–7), P = 0.007 (Day 8–10), Fig. 3c}.
IP-10 {P < 0.01 (Day 3–5), P < 0.01 (Day 6–7), P < 0.01
(Day 8–10), P = 0.037 (Day 14–17), Fig. 3a} and MCP-1
{P < 0.01 (Day 3–5), P < 0.01 (Day 6–7), P = 0.040 (Day
8–10), P = 0.500 (Day 14–17), Fig. 3b} were higher in
dengue patients compared with healthy controls. They
displayed similar decreasing trends throughout the dis-
ease progress. Significant differences of IP-10 (P =
0.002, Fig. 3a) and MCP-1 (P = 0.007, Fig. 3b) were
noted between mild and severe dengue patients on day
8–10, with continually decreasing trends in mild pa-
tients but not in severe patients. Level of RANTES was
lower in severe dengue patients compared to mild pa-
tients and healthy controls on day 6–7 (P = 0.002 versus
healthy controls, P = 0.024 versus mild patients) and 8–
GRO



















Mild dengue (n = 30) 
3-5 d (n = 10)
6-7 d (n = 18)
8-10 d (n = 19 )
14-17d (n = 6)
Severe dengue (n = 21)
3-5 d (n = 3)
6-7 d (n = 9)
8-10 d (n = 11)
14-17d (n = 5)
Controls (n = 10)
Fig. 3 Different trends of chemokines throughout the disease were exhibited between mild and severe dengue patients. IP-10 (a) and MCP-1 (b)
were higher in dengue patients compared with healthy controls. They displayed similar decreasing trends throughout the whole disease process.
Significant differences of IP-10 and MCP-1 were noted between mild and severe dengue patients on day 8-10, with continually decreasing trends
in mild patients but not in severe patients. IL-8 (c) was higher in severe patients than mild patients and showed decreasing trends as patients
recovered. Levels of RANTES (d) and GRO-α (e) were lower in severe dengue patients. No difference of eotaxin-1 (f) and MDC (g) in dengue
patients was observed compared to healthy controls
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10 (P = 0.001 versus healthy controls, P = 0.012 versus
mild patients) of illness (Fig. 3d). GRO-α was similar to
RANTES but a significant difference was noted only on
day 6–7 of illness between mild and severe dengue pa-
tients (P = 0.034, Fig. 3e). No difference was observed be-
tween dengue patients and healthy controls in eotaxin-1
(P > 0.05, Fig. 3f) and MDC (P > 0.05, Fig. 3g).
Adhesion molecules
With regard to adhesion molecules, sVCAM-1 {P < 0.01
(Day 3–5), P < 0.01 (Day 6–7), P < 0.01 (Day 8–10), P =
0.036 (Day 14–17), Fig. 4a} were significantly higher and
sICAM-1 (P > 0.05, Fig. 4b) were normal in dengue pa-
tients compared to healthy controls. Different trends of
sVCAM-1 were observed between mild and severe pa-
tients as shown in Fig. 4a. Level of sVCAM-1 was dis-
played decreasing trend after day 6–7 in mild dengue
patients while after day 8–10 in severe ones (Fig. 4a).
Discussion
As we know, inflammation is an innate immune re-
sponse to infection and supposed to be protective.
However, nonresolving inflammation is a major trigger
of disease and turns destructive [15]. Hence multiple
mechanisms are evolved to resolve inflammation. Ef-
fector cells normally undergo apoptosis or differentiate
to other phenotypes. Cells like macrophages could
polarize from M1 towards M2 [16]. M1 macrophages
play key roles in triggering inflammation via secreting
pro-inflammatory factors, while M2 macrophages in-
volve in immunosuppression and tissue repair by re-
leasing series of anti-inflammatory mediators [17].
Discordance of those resolution mechanisms might re-
sult in excessive inflammation and detrimental out-
comes. In this study, the expression profile of several
important inflammation mediators, including TNF-α,
IL-1α, IL-1, IFN-γ and IL-10, was investigated in den-
gue patients at different time points. Our results
showed that there are significant differences between
mild and severe patients. Those results provided solid
evidence that inflammation played a pivotal role in de-
termining the severity of dengue disease.
Once infected by DENV, the hosts immediately trig-
gered an immune response to eliminate the virus. Simi-
lar to DENV, infections by other flaviviruses such as
West Nile Virus (WNV) and Japanese encephalitis virus
(JEV) also induce robust proinflammatory cytokine re-
sponses to cause immunopathology [18]. An appropri-
ate inflammatory response is protective and essential
for resistance to infection. Decreased or absent inflam-
matory response may lead to propagation of virus and
progression of disease. However, excessive inflamma-
tory response is believed to play a direct role in the
pathogenesis of severe dengue disease [19, 20]. Studies
have been reported that severe dengue patients display
uncontrolled immune cell activation and increased in-
flammation mediators production. Elevated mediators
change the activation status and function of the vascu-
lar endothelium and eventually lead to transient in-
crease in vascular permeability [20, 21]. We also found
high levels of inflammation mediators in severe patients
in this study.
TNF-α, as a classic pro-inflammatory cytokine, stimu-
lates the acute phase reaction. In this study elevated
TNF-α was observed in all dengue patients but higher
in severe cases. The important role of TNF-α in DENV
infection has been reported in many previous studies
[8, 22]. Although its inhibitory effect on DENV replica-
tion is benefit, TNF-α may also account for activation
of vascular endothelial cell and increase vascular per-
meability. TNF-α has been associated with hemorrhagic
manifestations of dengue [23]. Anti-TNF-α antibodies
treatment of DENV-infected mouse has shown effects
on preventing severe symptoms and reducing mortality
[24]. However, inconsistency or no differences of TNF-
α between different disease severity, even compared
with healthy controls have also been reported in some
studies [7]. This discrepancy could be due to TNF-α
genetic polymorphisms or differences of study popula-
tion. IL-1α, produced mainly by activated macrophages,
sICAM-1

















Mild dengue (n = 30) 
3-5 d (n = 10)
6-7 d (n = 18)
8-10 d (n = 19 )
14-17d (n = 6)
Severe dengue (n = 21)
3-5 d (n = 3)
6-7 d (n = 9)
8-10 d (n = 11)
14-17d (n = 5)
Controls (n = 10)
Fig. 4 Different trends of adhesion molecules were compared between mild and severe dengue patients. sVCAM-1 (a) were higher and sICAM-1
(b) were normal in dengue patients compared to healthy controls. Different trends of sVCAM-1 were observed between mild and severe patients
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is a member of IL-1 family like IL-1β. Increased IL-1β
in severe patients has been reported when compared to
mild cases [8]. However, Level of IL-1α in dengue pa-
tients has not been reported. In this study, increased
IL-1α during the course of illness was observed. There
were significant differences between mild and severe
cases on day 8–10 of illness. IFN-γ has been reported
to be associated with severity in many previous studies
[25, 26]. IFN-γ displayed similar trend as IL-1α in this
study. IL-10, as a central anti-inflammatory cytokine,
suppresses the expression of pro-inflammatory cyto-
kines, chemokines and adhesion molecules. Some study
found that level of IL-10 was higher during febrile
phase and correlate with the degree of plasma leakage
[27, 28]. But other study reported that IL-10 peaked
during defervescence as the body attempted to control
the acute systemic inflammatory response [26]. In this
study we observed that IL-10 peaked on day 6–7 in
mild patients, while in severe cases on day 8–10 of ill-
ness. This discrepancy of IL-10 provided evidence of
differences of inflammatory response between mild and
severe patients. Chemokines also displayed differences
between mild and severe dengue patients in this study.
IL-8 is a chemokine produced mainly by macrophages.
Similar to TNF-α, IL-8 is an innate immune mediator
and mediates acute phase reaction. The effects on
pathogenesis of severe dengue has been reported [26].
The trend of IL-8 in dengue patients was similar to
TNF-α in this study. IP-10 is secreted by several cell
types such as monocytes in response to IFN-γ and has
important role in disease initiation and progression.
Abnormal levels of IP-10 have been associated with in-
flammatory diseases [29]. In this study we observed sig-
nificantly higher levels of IP-10 in dengue patients. The
levels declined steadily in mild cases throughout the
disease. However, the levels rose again in severe cases
on day 8–10 of illness. This suggested that recurrent in-
flammatory response happened in severe cases. It can
explain the trend of IL-10 at the same time point. Peaks
of pro-inflammatory cytokines and peaks of anti-
inflammatory cytokines coexist. MCP-1 is a potent
monocytes chemotractant and has been reported that
increased levels correlated with severe dengue symp-
toms [30]. The results in this study also proved that
inflammation in severe dengue patients resolved differ-
ently from mild cases. However, lower levels of GRO-α
and RANTES were observed in severe patients on day
6-7 than mild cases in this study. A recent study re-
ported that RANTES levels were decreased in dengue
patients and correlated strongly with platelets count
and disease severity, similar to our results [9]. Lower
levels of RANTES in dengue patients could be due to
thrombocytopenia during defervescence particularly in
severe cases. That was because GRO-α and RANTES
were released by activated platelet [31]. Another study
also proved that platelets from DENV infected patients
secreted lower levels of RANTES in vitro than did
platelets from healthy individuals [32]. The mechanism
of decreased GRO-α may be the same as RANTES.
sVCAM-1 is released from the endothelial cell surface
into the circulation upon endothelial activation and now
proved to be a marker for endothelial injury under in-
flammatory processes [33]. Elevated levels of sVCAM-1
have been reported in dengue patients and associate
with severity of disease [34]. In this study higher levels
in severe dengue patients were observed than mild pa-
tients on day 8–10 of illness. Increased sVCAM-1 levels
in all dengue patients indicated that abnormal function
of vascular endothelial cells occurred after onset of ill-
ness as reported in another study. Evidence from serial
ultrasound studies also indicated that plasma leakage ac-
tually started at initial stage of disease in all patients
[35]. It is possible that most of patients experience some
degree of plasma leakage and only a minority gets worse.
There is no specific antiviral treatment and vaccine
currently available for DENV infection. Treatment is
largely supportive to alleviate of symptoms and prevent
shock by fluid resuscitation. Further investigations of
the mechanisms of severe disease may provide insight
into novel clinical management strategies. A number
of studies have shown excessive inflammation media-
tors in severe dengue patients [36]. Inflammation me-
diators during DENV infection, like a double-edged
sword, though anti-virus, may also account for in-
creased vascular permeability that characterizes severe
dengue [37, 38]. Defervescence, on around day 6–7 of
dengue disease, is a watershed for disease progression
that patients can either recover rapidly or progress to a
severe life-threatening stage. As we observed in this
study, most significant differences were noted on day
8–10 of illness between mild and severe dengue pa-
tients. That is, inflammation was very rapidly resolved
in mild patients but not in severe cases. So suppression
or pro-resolution of inflammation could be a potential
therapeutic approach for treatment of severe dengue.
Conclusion
Our results revealed the coexistence of excessive inflam-
matory response and slow resolution of inflammation in
severe adult dengue patients. Thus, excessive inflamma-
tory response or failed termination of inflammation
usually contributes to the pathogenesis of severe den-
gue disease. Therefore, it is possible to introduce drugs
with anti-inflammatory or pro-resolving effects to
current therapeutic regimen, which might prevent se-
vere disease development and decrease dengue mortal-
ity. Our study provides substantial evidence to support
such hypothesis.
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